237 related articles for article (PubMed ID: 30470647)
1. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
[TBL] [Abstract][Full Text] [Related]
2. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
Jobczyk M; Stawiski K; Fendler W; Różański W
Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
[TBL] [Abstract][Full Text] [Related]
3. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
4. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
[TBL] [Abstract][Full Text] [Related]
5. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
[TBL] [Abstract][Full Text] [Related]
6. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
7. Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
Pazır Y; Esmeray A; Gelmis M; Caglar U; Ozgor F; Sarılar O; Akbulut F
Urol J; 2024 May; 21(3):169-174. PubMed ID: 38493314
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
Krajewski W; Aumatell J; Subiela JD; Nowak Ł; Tukiendorf A; Moschini M; Basile G; Poletajew S; Małkiewicz B; Del Giudice F; Maggi M; Chung BI; Cimadamore A; Galosi AB; Fave RFD; D'Andrea D; Shariat SF; Hornak J; Babjuk M; Chorbińska J; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Panunzio A; Alvarez-Maestro M; Simone G; Mastroianni R; Łaszkiewicz J; Lonati C; Zamboni S; Simeone C; Niedziela Ł; Candela L; Macek P; Contieri R; Hidalgo BG; Rivas JG; Sosnowski R; Mori K; Mir C; Soria F; González-Padilla DA; Faba ÒR; Palou J; Ploussard G; Rajwa P; Hałoń A; Laukhtina E; Pradere B; Tully K; Burgos FJ; Cidre MÁJ; Szydełko T;
Urol Oncol; 2022 Nov; 40(11):491.e11-491.e19. PubMed ID: 35851185
[TBL] [Abstract][Full Text] [Related]
9. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
Sylvester RJ; Rodríguez O; Hernández V; Turturica D; Bauerová L; Bruins HM; Bründl J; van der Kwast TH; Brisuda A; Rubio-Briones J; Seles M; Hentschel AE; Kusuma VRM; Huebner N; Cotte J; Mertens LS; Volanis D; Cussenot O; Subiela Henríquez JD; de la Peña E; Pisano F; Pešl M; van der Heijden AG; Herdegen S; Zlotta AR; Hacek J; Calatrava A; Mannweiler S; Bosschieter J; Ashabere D; Haitel A; Côté JF; El Sheikh S; Lunelli L; Algaba F; Alemany I; Soria F; Runneboom W; Breyer J; Nieuwenhuijzen JA; Llorente C; Molinaro L; Hulsbergen-van de Kaa CA; Evert M; Kiemeney LALM; N'Dow J; Plass K; Čapoun O; Soukup V; Dominguez-Escrig JL; Cohen D; Palou J; Gontero P; Burger M; Zigeuner R; Mostafid AH; Shariat SF; Rouprêt M; Compérat EM; Babjuk M; van Rhijn BWG
Eur Urol; 2021 Apr; 79(4):480-488. PubMed ID: 33419683
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guérin and the Relationship with the CUETO Scoring Model.
Chung JW; Kim JW; Lee EH; Chun SY; Park DJ; Byeon KH; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Ha YS; Kim TH
Urol J; 2021 Oct; 19(4):281-288. PubMed ID: 34655075
[TBL] [Abstract][Full Text] [Related]
11. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system.
Leo MC; McMullen CK; O'Keeffe-Rosetti M; Weinmann S; Garg T; Nielsen ME
Urol Oncol; 2020 Feb; 38(2):39.e21-39.e27. PubMed ID: 31711836
[TBL] [Abstract][Full Text] [Related]
12. Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
Miyake M; Kitamura H; Nishimura N; Miyamoto T; Nakahama T; Fujii T; Matsumoto H; Matsuyama H; Yonemori M; Enokida H; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Nishiyama H; Fujimoto K;
BJUI Compass; 2024 Mar; 5(2):269-280. PubMed ID: 38371197
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guérin Therapy in Non-Muscle-Invasive Bladder Cancer.
Ślusarczyk A; Garbas K; Pustuła P; Zapała Ł; Radziszewski P
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730636
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
Contieri R; Hurle R; Paciotti M; Casale P; Saita A; Porpiglia F; Fiori C; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Cantiello F; Damiano R; Borghesi M; Bove P; Bertolo R; Papalia R; Mari A; Luzzago S; Mistretta FA; Soria F; Gontero P; Marchioni M; LA Civita E; Terracciano D; Russo GI; Schips L; Perdona S; Mirone V; Tataru OS; Musi G; Vartolomei MD; Autorino R; Montanari E; DE Cobelli O; Ferro M
Minerva Urol Nephrol; 2023 Apr; 75(2):180-187. PubMed ID: 36197700
[TBL] [Abstract][Full Text] [Related]
17. Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model.
Dovey Z; Pfail J; Martini A; Steineck G; Dey L; Renström L; Hosseini A; Sfakianos JP; Wiklund P
Urol Oncol; 2022 Mar; 40(3):106.e1-106.e10. PubMed ID: 34840075
[TBL] [Abstract][Full Text] [Related]
18. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
